Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06IQE
|
|||
| Former ID |
DIB008028
|
|||
| Drug Name |
H1N1 influenza vaccine
|
|||
| Synonyms |
GC-1116; Greenflu-S Plus; H1N1 influenza vaccine (MF59-adjuvanted); H1N1 influenza vaccine (MF59-adjuvanted), Korea Green Cross
Click to Show/Hide
|
|||
| Drug Type |
Vaccine
|
|||
| Indication | Influenza virus infection [ICD-11: 1E30-1E32] | Discontinued in Phase 3 | [1] | |
| Company |
Green Cross Corp
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cell mediated immunity response (CMIR) | Target Info | . | [2], [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800039884) | |||
| REF 2 | Risk factors affecting seroconversion after influenza A/H1N1 vaccination in hemodialysis patients. BMC Nephrol. 2012 Dec 3;13:165. | |||
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.